Vera Therapeutics Quarterly Cash Flow Statement
NASDAQ: VERAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
29.88+0.15 (+0.50%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vera Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Vera Therapeutics generated -$100.3 million of operating cash flow and spent $0 on capital expenditures. That left free cash flow of -$100.3 million.
Summary generated from market data by MetaCap's automated system. Methodology
Vera Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -109.47M | -121.03M | -91.10M | -80.29M | -76.53M | -51.69M | -43.42M | -46.63M | -33.71M | -28.38M | -25.66M | -20.10M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 132.00K | 140.00K | 135.00K | 129.00K | 119.00K | 85.00K | 55.00K | 24.00K | 15.00K | 11.00K | 4.00K | 6.00K |
| Stock-Based Compensation | 15.86M | 13.21M | 10.96M | 9.74M | 9.47M | 7.74M | 6.22M | 5.59M | 4.87M | 4.12M | 3.22M | 2.92M |
| Change in Working Capital | -6.26M | -13.55M | 10.46M | 9.31M | 13.71M | -9.06M | -208.00K | 6.16M | 6.75M | -7.99M | -1.43M | -4.26M |
| Operating Cash Flow | -100.25M | -106.50M | -69.99M | -61.91M | -54.80M | -54.41M | -39.18M | -36.88M | -24.78M | -33.83M | -25.14M | -22.97M |
| Capital Expenditures | 0 | -23.00K | -102.00K | -133.00K | -208.00K | -187.00K | -645.00K | -238.00K | -89.00K | 0 | -63.00K | 0 |
| Investing Cash Flow | 32.86M | -137.82M | 80.66M | 69.76M | 28.54M | 15.32M | -221.38M | 38.32M | -22.68M | -219.29M | 18.56M | 16.23M |
| Share Repurchases | — | — | 0 | — | — | — | 0 | — | — | — | 0 | — |
| Financing Cash Flow | 1.92M | 3.94M | 286.28M | 797.00K | 20.29M | 1.53M | 325.95M | 739.00K | 3.44M | 276.54M | 24.83M | 297.00K |
| Net Change in Cash | -65.47M | -240.37M | 296.95M | 8.65M | -5.97M | -37.56M | 65.39M | 2.17M | -44.02M | 23.42M | 18.24M | -6.45M |
| Free Cash Flow | -100.25M | -106.52M | -70.10M | -62.04M | -55.01M | -54.59M | -39.83M | -37.12M | -24.87M | -33.83M | -25.21M | -22.97M |
This table shows 12 quarterly periods of Vera Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow VERA's reporting calendar. What is a cash flow statement?